Sotac Pharmaceuticals (NSE:SOTAC) Total Liabilities: ₹689.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SOTAC Sotac Pharmaceuticals Ltd NSE:SOTAC
58 GF Score
Price ₹100.00
GF Value ₹140.82
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sotac Pharmaceuticals Total Liabilities?

Sotac Pharmaceuticals NSE:SOTAC 58 Total Liabilities is ₹689.0 Mil as of Mar. 2026. GuruFocus rates NSE:SOTAC with a GF Score™ of 58/100 and a GF Value™ of ₹140.82 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Sotac Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was ₹689.0 Mil.

Sotac Pharmaceuticals's quarterly Total Liabilities declined from Mar. 2025 (₹659.06 Mil) to Sep. 2025 (₹622.75 Mil) but then increased from Sep. 2025 (₹622.75 Mil) to Mar. 2026 (₹688.99 Mil).

Sotac Pharmaceuticals's annual Total Liabilities increased from Mar. 2024 (₹559.98 Mil) to Mar. 2025 (₹659.06 Mil) and increased from Mar. 2025 (₹659.06 Mil) to Mar. 2026 (₹688.99 Mil).

Sotac Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Sotac Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sotac Pharmaceuticals Total Liabilities Chart

Sotac Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial 286.32 539.54 559.98 659.06 688.99

Sotac Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 559.98 645.75 659.06 622.75 688.99
NSE:SOTAC
58GF Score
Sotac Pharmaceuticals Ltd NSE:SOTAC
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sotac Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sotac Pharmaceuticals's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=583.598+(103.878+1.51
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=689.0

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=1334.704-645.718
=689.0

Sotac Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=583.598+(103.878+1.51
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=689.0

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=1334.704-645.718
=689.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ₹689.0 Mil mean?
Sotac Pharmaceuticals (NSE:SOTAC) has a Total Liabilities of ₹689.0 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sotac Pharmaceuticals and its competitors.
Is Sotac Pharmaceuticals' Total Liabilities too high?
Sotac Pharmaceuticals' current Total Liabilities is ₹689.0 Mil. Overall, Sotac Pharmaceuticals has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' Total Liabilities compare to ZTS and UTHR?
Sotac Pharmaceuticals' Total Liabilities of ₹689.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sotac Pharmaceuticals and its competitors. Sotac Pharmaceuticals's current Total Liabilities is ₹689.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹140.82, compared to a current price of ₹100.00 — trading 29% below its estimated fair value. The current Total Liabilities is ₹689.0 Mil. Sotac Pharmaceuticals' overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current Total Liabilities is ₹689.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?

Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued. The current stock price of ₹100.00 is trading 29% below its estimated GF Value™ of ₹140.82. GuruFocus considers Sotac Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for NSE:SOTAC:

  • Total Liabilities: ₹689.0 Mil
  • GF Value™: ₹140.82 vs. price of ₹100.00 (29% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sotac Pharmaceuticals Business Description

Address Plot No. PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Sanand, Ahmedabad, GJ, IND, 382110
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
58GF Score

Get the complete analysis for NSE:SOTAC

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹100.00
Price
₹140.82
GF Value